Dataset Information

Exercise Capacity and Quality of Life in Pulmonary Arterial Hypertension.

ABSTRACT:

Background

Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease with a high mortality rate that can be divided into different groups according to etiology and prognosis. Few studies have investigated differences in the exercise capacity and quality of life (QOL) among the different groups of PAH patients. Therefore, we aimed to (1) compare the hemodynamic exercise responses between patients with idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with other diseases (APAH), and (2) determine the factors associated with exercise capacity in patients with PAH.

Methods

Six patients diagnosed with IPAH and eight with APAH [congenital heart disease (CHD)-dominant PAH] were included in this study. The main outcome measures included body composition, exercise capacity, hemodynamic measurements, physical activity levels, fatigue severity, and QOL.

Results

The CHD-dominant PAH group had a significantly lower predicted peak oxygen consumption (VO_2pred %), pressure of end-tidal carbon dioxide at the peak and at anaerobic threshold (PETCO_2peak and PETCO_2@AT), and significantly elevated ventilatory equivalent (VE/VCO_2slope and VE/VCO_2@AT) compared with the IPAH group. Multiple regression analysis indicated that PETCO_2@AT was significantly associated with either VO_2peak (? = 0.805, adjusted R² = 0.619, p = 0.001) or 6-minute walk distance (? = 0.816, adjusted R² = 0.638, p < 0.001).

Conclusions

Patients with CHD-dominant PAH had poor exercise capacity and exercise responses compared to those with IPAH. Evaluating exercise capacity and the patient response to exercise using cardiopulmonary exercise testing is increasingly important in view of the etiology of PAH.

SUBMITTER: Chen LW

PROVIDER: S-EPMC7814335 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Exercise Capacity and Quality of Life in Pulmonary Arterial Hypertension.

Chen Ling-Wei LW Chen Ssu-Yuan SY Hsu Hsao-Hsun HH Wu Yen-Wen YW Lai Yu-Mei YM Chien Meng-Yueh MY

Acta Cardiologica Sinica 20210101 1

<h4>Background</h4>Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease with a high mortality rate that can be divided into different groups according to etiology and prognosis. Few studies have investigated differences in the exercise capacity and quality of life (QOL) among the different groups of PAH patients. Therefore, we aimed to (1) compare the hemodynamic exercise responses between patients with idiopathic pulmonary arterial hypertension (IPAH) and PAH associ ...[more]

PMID: 33488030

Similar Datasets

Project description:BackgroundFlolan (epoprostenol sodium) is most commonly prescribed to patients with severe pulmonary arterial hypertension (PAH) owing to the requirement that the drug be delivered by continuous intravenous infusion and the reconstituted solution may only be administered up to 24 hours when it is maintained between a temperature of 2°C and 8°C. The aim of this single-arm, open label study was to describe the effects of the new thermostable formulation of Flolan on health-related quality of life (HRQoL) and ease of administration in subjects switching from the currently marketed Flolan to the reformulated product.MethodsFollowing a 4-week run-in period and after 4 weeks of treatment with the reformulated product, patients completed the SF-36 HRQoL questionnaire and a study-specific questionnaire evaluating ease of administration, along with World Health Organization (WHO) functional class, six-minute walked distance (6MWD) and N-terminal-pro B-type natriuretic peptide (NT-proBNP) assessment.Results16 participants completed the study. The SF-36 scores remained unchanged from baseline to Week 4. Conversely, there were small improvements for the majority of the study-specific questionnaire items and 14 (88%) subjects preferred the reformulated product to the currently marketed Flolan. There was no significant change in the dose of reformulated product, 6MWD, Borg dyspnoea index, WHO functional class and mean NT-proBNP levels. No significant changes in haemodynamic parameters were seen from baseline to 2 hours post transition in a subset of patients undergoing catheterization.ConclusionThe reformulated product was not associated with significant improvement in HRQoL compared with the currently marketed Flolan as measured by the SF-36. However, most subjects preferred the reformulated product to the currently marketed Flolan. Moreover, the 2 formulations of Flolan had similar safety and efficacy profiles.Trial registrationClinicalTrials.gov NCT01462565.

Dataset Information

Exercise Capacity and Quality of Life in Pulmonary Arterial Hypertension.

Background

Methods

Results

Conclusions

Publications

Exercise Capacity and Quality of Life in Pulmonary Arterial Hypertension.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure